Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI aims to speed up brain scan reports for urgent cases

NCT ID NCT07671664

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests an AI tool called MIDI that quickly spots problems in brain MRI scans. The goal is to see if it helps doctors report urgent scans faster, so patients get treatment sooner. Over 100,000 adults will take part across multiple NHS sites in the UK.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MIDI, an AI-based triage tool for brain MRI scans
What this could lead to
If successful, this could show that AI can help doctors prioritize urgent brain scans, leading to faster diagnoses and treatment for patients.
What could go wrong
This is a large trial but still early in real-world testing. The AI may not always work as expected, and its impact on patient outcomes is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100,800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For main trial * Adult patient (≥ 18 years of age) at the time of MRI. * Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm). * Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution. For O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who consent to completing the staff survey For O7 subgroup * Adult patient (≥ 18 years of age) at the time of MRI. * Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm). * Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution. * Patient with suspected de novo stroke/TIA in TIA/Stroke pathway. * Patient with suspected de novo stroke/TIA in Acute Neurology pathway. * Patient with suspected de novo stroke/TIA identified via SSNAP review. For O8 subgroup * Adult patient (≥ 18 years of age) at the time of MRI. * Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm). * Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution. * Patient with stage III/IV malignant melanoma undergoing regular surveillance MRI brain scans presenting with de novo brain metastases. * Patient with lung cancer undergoing pre-radical treatment staging MRI brain scans presenting with de novo brain metastases. * Patients with de novo symptomatic brain metastases secondary to melanoma and/or lung cancer and/or breast cancer detected on MRI brain scans from all patient pathways. Additionally for those completing EORTC questionnaires: ● Able to give consent and likely to be able to complete EORTC questionnaires. Exclusion Criteria: For main trial * Patient is under 18 years of age at the time of MRI. * Brain MRI scan not performed at a participating NHS site or outside the defined study period. * Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out. * Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution. For O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who do not consent to completing the staff survey For O7 subgroup * Patient is under 18 years of age at the time of MRI. * Brain MRI scan not performed at a participating NHS site or outside the defined study period. * Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out. * Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution. * Patient without suspected de novo stroke/TIA or not on TIA/Stroke pathway. * Patient without suspected de novo stroke/TIA or not on Acute Neurology pathway. For O8 subgroup * Patient is under 18 years of age at the time of MRI. * Brain MRI scan not performed at a participating NHS site or outside the defined study period. * Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out. * Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution. * Patient without stage III/IV malignant melanoma, or not undergoing regular surveillance MRI brain scans, or not presenting with de novo brain metastases. * Patient without lung cancer undergoing pre-radical treatment staging MRI brain scans, or not presenting with de novo brain metastases. * Patients without de novo symptomatic brain metastases secondary to melanoma and/or lung cancer and/or breast cancer detected on MRI brain scans. Additionally for those completing EORTC questionnaires: ● Unable to give consent and unlikely to be able to complete EORTC questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.